NACI Update on Pediatric Invasive Pneumococcal Disease and Recommended Use of Conjugate Pneumococcal Vaccines - June 2010

An article from the "Canada Communicable Disease Report" (CCDR), Volume 36 • ACS-3, June 2010. This statement provides an update on the epidemiology of pneumococcal disease since the introduction of Prevnar® (Wyeth Pharmaceuticals), as well as information regarding a newly authorized conjugate vaccine against pneumococcal disease, Synflorix™ (GlaxoSmithKline Inc.). Source: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/10vol36/acs-3/index-eng.php